Hims & Hers Class Action Lawsuit Filed Over Securities Fraud Allegations.

A class action lawsuit has been filed against Hims & Hers Health, Inc. over allegations of securities fraud and unlawful business practices. Investors who purchased or acquired Hims & Hers securities during the Class Period may request the Court to appoint them as Lead Plaintiff. The lawsuit concerns the company's long-term commitment to its core business, which was announced on April 29, 2025.

Investors in Hims & Hers Health, Inc. (NYSE: HIMS) are being notified of a class action securities lawsuit alleging fraudulent practices and misleading statements. The lawsuit, filed in the United States District Court for the Northern District of California, seeks to recover losses on behalf of investors who were adversely affected between April 29, 2025, and June 23, 2025 [1].

The complaint alleges that the company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that Hims was engaged in the deceptive promotion and selling of illegitimate, knockoff versions of Wegovy®, which posed a risk to patient safety. Additionally, it is alleged that there was a substantial risk that the company's collaboration with Novo Nordisk would be terminated as a result of these actions, and that the company's positive statements about its business, operations, and prospects were materially misleading [2].

On June 23, 2025, Novo Nordisk announced that it was ending its partnership with Hims, citing the company's failure to adhere to laws prohibiting mass sales of compounded drugs under false pretenses. This announcement led to a significant drop in Hims' stock price, falling by $22.24 or 34.6%, to close at $41.98 per share [3].

Investors who suffered losses during the relevant time frame are encouraged to contact legal firms such as Levi & Korsinsky, LLP and Faruqi & Faruqi, LLP to discuss their options. The deadline to request the Court to appoint them as lead plaintiff is August 25, 2025 [1][2].

The lawsuit underscores the importance of transparency and accurate disclosures in corporate reporting. Investors are urged to remain vigilant and seek legal advice if they believe they may have been affected by the alleged misconduct.

References:
[1] https://www.globenewswire.com/news-release/2025/07/11/3114271/3080/en/Levi-Korsinsky-Reminds-Hims-Hers-Health-Inc-Investors-of-the-Pending-Class-Action-Lawsuit-with-a-Lead-Plaintiff-Deadline-of-August-25-2025-HIMS.html
[2] https://www.morningstar.com/news/pr-newswire/20250708ny25292/hims-investors-have-the-opportunity-to-lead-the-hims-hers-health-securities-fraud-lawsuit-with-faruqi-faruqi-llp
[3] https://www.marketscreener.com/quote/stock/HIMS-HERS-HEALTH-INC-65220697/news/HIMS-HERS-HEALTH-CLAIMSFILER-REMINDS-INVESTORS-WITH-LOSSES-IN-EXCESS-OF-100-000-of-Lead-Plaintiff-50494420/